Pheochromocytoma and paraganglioma with negative results for urinary metanephrines show higher risks for metastatic diseases.

Adrenal Gland Neoplasms / diagnostic imaging Cohort Studies Cross-Sectional Studies Humans Metanephrine Negative Results Paraganglioma / diagnostic imaging Pheochromocytoma Retrospective Studies
Catecholamine MIBG Metastasis Paraganglioma Pheochromocytoma

Journal

Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444

Informations de publication

Date de publication:
10 2021
Historique:
received: 20 03 2021
accepted: 29 06 2021
pubmed: 18 7 2021
medline: 26 10 2021
entrez: 17 7 2021
Statut: ppublish

Résumé

Few studies have assessed the clinical features of pheochromocytoma and paraganglioma (PPGL) not producing excessive catecholamine. We aimed to clarify the clinical characteristics of PPGL patients with negative results for urinary metanephrines. This is a retrospective cross-sectional study. We established a database by combining datasets from the Nationwide Cohort Study on the Development of Diagnosis and Treatment of Pheochromocytoma in Japan (PHEO-J) and the Advancing Care and Pathogenesis of Intractable Adrenal diseases in Japan (ACPA-J). We compared the clinical differences between PPGL patients with negative results for urinary metanephrines and those with catecholamine-producing PPGL. Five hundred PPGL patients in the combined database were analyzed. Among them, 31 were negative for metanephrines. PPGL with negative results for urinary metanephrines was significantly associated with extra-adrenal disease (Odds ratio (OR) 6.58, 95% CI (confidence interval) 3.03-14.3, p < 0.001), the presence of metastatic disease (OR 4.22, 95% CI 1.58-11.3, p = 0.004), and negativity on meta-iodobenzylguanidine (MIBG) scintigraphy (OR 0.15, 95% CI 0.03-0.77, p = 0.023). Our findings demonstrate that PPGL patients with negative results for urinary metanephrines are associated with extra-adrenal lesions, metastatic disease, and negative MIBG findings. This suggests that PPGL patients with negative results for urinary metanephrines have a greater need for systemic whole-body imaging other than MIBG scintigraphy and close follow-up to monitor for metastasis than do patients with PPGL overtly producing excessive catecholamine.

Identifiants

DOI: 10.1007/s12020-021-02816-9 PMID: 34272648
pubmed: 34272648
doi: 10.1007/s12020-021-02816-9
pii: 10.1007/s12020-021-02816-9
doi:

Substances chimiques

Metanephrine 5001-33-2

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

155-162

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Références

J.W. Lenders, G. Eisenhofer, M. Mannelli, K. Pacak,, Pheochromocytoma. Lancet. 366, 665–675 (2005). https://doi.org/10.1016/S0140-6736(05)67139-5
doi: 10.1016/S0140-6736(05)67139-5 pubmed: 16112304
A.M.A. Berends, E. Buitenwerf, R.R. de Krijger, N.J.G.M. Veeger, A.N.A. van der Horst-Schrivers, T.P. Links, M.N. Kerstens,, Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: a nationwide study and systematic review. Eur. J. Intern. Med. 51, 68–73 (2018). https://doi.org/10.1016/j.ejim.2018.01.015
doi: 10.1016/j.ejim.2018.01.015 pubmed: 29361475
G. Eisenhofer, H. Keiser, P. Friberg, E. Mezey, T.T. Huynh, B. Hiremagalur, T. Ellingson, S. Duddempudi, A. Eijsbouts, J.W. Lenders, Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J. Clin. Endocrinol. Metab. 83(6), 2175–2185 (1998). https://doi.org/10.1210/jcem.83.6.4870
doi: 10.1210/jcem.83.6.4870 pubmed: 9626157
J.W. Lenders, Q.Y. Duh, G. Eisenhofer, A.P. Gimenez-Roqueplo, S.K.G. Grebe, M.H. Murah, M. Naruse, K. Pacak, W.F. Young Jr., Endocrine society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99(6), 1915–1942 (2014). https://doi.org/10.1210/jc.2014-1498
doi: 10.1210/jc.2014-1498 pubmed: 24893135 pmcid: 24893135
M.G. Heavner, L.S. Krane, S.M. Winters, M. Mirzazadeh, Pheochromocytoma diagnosed pathologically with previous negative serum markers. J. Surg. Oncol. 112(5), 492–495 (2015). https://doi.org/10.1002/jso.24031
doi: 10.1002/jso.24031 pubmed: 26384104
K.A. Vanderveen, S.M. Thompson, M.R. Callstrom, W.F. Young Jr, C.S. Grant, D.R. Farley, M.L. Richards, G.B. Thompson, Biopsy of pheochromocytomas and paragangliomas: potential for disaster. Surgery 146(6), 1158–1166 (2009). https://doi.org/10.1016/j.surg.2009.09.013
doi: 10.1016/j.surg.2009.09.013 pubmed: 19958944
J.W. Lenders, K. Pacak, M.M. Walther, W.M. Linehan, M. Mannelli, P. Friberg, H.R. Keiser, D.S. Goldstein, G. Eisenhofer, Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287(11), 1427–1434 (2002). https://doi.org/10.1001/jama.287.11.1427
doi: 10.1001/jama.287.11.1427 pubmed: 11903030
G. Eisenhofer, A. Prejbisz, M. Peitzsch, C. Pamporaki, J. Masjkur, N. Rogowski-Lehmann, K. Langton, E. Tsourdi, M. Pęczkowska, S. Fliedner, T. Deutschbein, F. Megerle, H.J.L.M. Timmers, R. Sinnott, F. Beuschlein, M. Fassnacht, A. Januszewicz, J.W.M. Lenders, Biochemical diagnosis of chromaffin cell tumors in patients at high and low risk of disease: plasma versus urinary free or deconjugated O-Methylated Catecholamine metabolites. Clin. Chem. 64(11), 1646–1656 (2018). https://doi.org/10.1373/clinchem.2018.291369
doi: 10.1373/clinchem.2018.291369 pubmed: 30097498
O. Hamidi, W.F. Young Jr, N.M. Iñiguez-Ariza, N.E. Kittah, L. Gruber, C. Bancos, S. Tamhane, I. Bancos, Malignant pheochromocytoma and paraganglioma:272 patients over 55 years. J. Clin. Endocrinol. Metab. 102(9), 3296–3305 (2017). https://doi.org/10.1210/jc.2017-00992
doi: 10.1210/jc.2017-00992 pubmed: 28605453 pmcid: 5587061
F. Feng, Y. Zhu, X. Wang, Y. Wu, W. Zhou, X. Jin, R. Zhang, F. Sun, Z. Kasoma, Z. Shen, Predictive factors for malignant pheochromocytoma: analysis of 136 patients. J. Urol. 185(5), 1583–1590 (2011). https://doi.org/10.1016/j.juro.2010.12.050
doi: 10.1016/j.juro.2010.12.050 pubmed: 21419457
A.P. Gimenez-Roqueplo, J. Favier, P. Rustin, C. Rieubland, M. Crespin, V. Nau, P. Khau Van Kien, P. Corvol, P.F. Plouin, X. Jeunemaitre, COMETE network.: mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res. 63(17), 5615–5621 (2003)
pubmed: 14500403
L. Amar, J. Bertherat, E. Baudin, C. Ajzenberg, B. Bressac-de Paillerets, O. Chabre, B. Chamontin, B. Delemer, S. Giraud, A. Murat, P. Niccoli-Sire, S. Richard, V. Rohmer, J.L. Sadoul, L. Strompf, M. Schlumberger, X. Bertagna, P.F. Plouin, X. Jeunemaitre, A.P. Gimenez-Roqueplo, Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol. 23(34), 8812–8818 (2005). https://doi.org/10.1200/JCO.2005.03.1484
doi: 10.1200/JCO.2005.03.1484 pubmed: 16314641
H.J. Timmers, K. Pacak, T.T. Huynh, M. Abu-Asab, M. Tsokos, M.J. Merino, B.E. Baysal, K.T. Adams, G. Eisenhofer, Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. J. Clin. Endocrinol. Metab. 93(12), 4862–4832 (2008). https://doi.org/10.1210/jc.2008-1093
doi: 10.1210/jc.2008-1093
K.M.A. Dreijerink, J.A. Rijken, C.J. Compaijen, H.J.L.M. Timmers, A.N.A. van der Horst-Schrivers, R.S. van Leeuwaarde, P.S. van Dam, C.R. Leemans, E.W.C.M. van Dam, C. Dickhoff, C.J. Dommering, P. de Graaf, G.J.C. Zwezerijnen, P. van der Valk, C.W. Menke-Van der Houven van Oordt, E.F. Hensen, E.P.M. Corssmit, E.M.W. Eekhoff, Biochemically silent sympathetic paraganglioma, pheochromocytoma, or metastatic disease in SDHD mutation carriers. J. Clin. Endocrinol. Metab. 104(11), 5421–5426 (2019). https://doi.org/10.1210/jc.2019-00202
doi: 10.1210/jc.2019-00202 pubmed: 31194241
H.P. Neumann, C. Pawlu, M. Peczkowska, B. Bausch, S.R. McWhinney, M. Muresan, M. Buchta, G. Franke, J. Klisch, T.A. Bley, S. Hoegerle, C.C. Boedeker, G. Opocher, J. Schipper, A. Januszewicz, C. Eng; European-American Paraganglioma Study Group, Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292(8), 943–951 (2004). https://doi.org/10.1001/jama.292.8.943
doi: 10.1001/jama.292.8.943 pubmed: 15328326
H.J. Timmers, C.C. Chen, J.A. Carrasquillo, M. Whatley, A. Ling, G. Eisenhofer, K.S. King, J.U. Rao, R.A. Wesley, K.T. Adams, K. Pacak, Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography. J. Natl. Cancer Inst. 104(9), 700–708 (2012). https://doi.org/10.1093/jnci/djs188
doi: 10.1093/jnci/djs188 pubmed: 22517990 pmcid: 3341309
J. Park, C. Song, M. Park, S. Yoo, S.J. Park, S. Hong, B. Hong, C.S. Kim, H. Ahn, Predictive characteristics of malignant pheochromocytoma. Korean J. Urol. 52(4), 241–246 (2011). https://doi.org/10.4111/kju.2011.52.4.241
doi: 10.4111/kju.2011.52.4.241 pubmed: 21556209 pmcid: 3085615
E. Grouzmann, O. Tschopp, F. Triponz, M. Matter, S. Bilz, M. Brändle, T. Drechser, S. Sigrist, H. Zulewski, C. Henzen, S. Fischli, K. Abid, Catecholamine metabolism in paraganglioma and pheochromocytoma: similar tumors in different sites? PLoS ONE 10(5), e0125426 (2015). https://doi.org/10.1371/journal.pone.0125426
doi: 10.1371/journal.pone.0125426 pubmed: 25946206 pmcid: 4422698
G. Eisenhofer, J.W. Lenders, G. Siegert, S.R. Bornstein, P. Friberg, D. Milosevic, M. Mannelli, W.M. Linehan, K. Adams, H.J. Timmers, K. Pacak, Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status. Eur. J. Cancer 48(11), 1739–1749 (2012). https://doi.org/10.1016/j.ejca.2011.07.016
doi: 10.1016/j.ejca.2011.07.016 pubmed: 22036874
G. Eisenhofer, M.M. Walther, T.T. Huynh, S.T. Li, S.R. Bornstein, A. Vortmeyer, M. Mannelli, D.S. Goldstein, W.M. Linehan, J.W. Lenders, K. Pacak, Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J. Clin. Endocrinol. Metab. 86(5), 1999–2008 (2001). https://doi.org/10.1210/jcem.86.5.7496
doi: 10.1210/jcem.86.5.7496 pubmed: 11344198
H.J.L.M. Timmers, C.C. Chen, J.A. Carrasquillo, M. Whatley, A. Ling, B. Havekes, G. Eisenhofer, L. Martiniova, K.T. Adams, K. Pacak, Comparison of
doi: 10.1210/jc.2009-1248 pubmed: 19864450 pmcid: 2795662
I. Ilias, C.C. Chen, J.A. Carrasquillo, M. Whatley, A. Ling, K.T. Adams, S. Perera, K. Pacak, Comparison of 6-
doi: 10.2967/jnumed.108.052373 pubmed: 18794260
J.H. Kim, H. Moon, J. Noh, J. Lee, S.G. Kim, Epidemiology and prognosis of pheochromocytoma/paraganglioma in Korea: a nationwide study based on the national health insurance service. Endocrinol. Metab. 35(1), 157–164 (2020). https://doi.org/10.3803/EnM.2020.35.1.157
doi: 10.3803/EnM.2020.35.1.157
S.M. Zuber, V. Kantorovich, K. Pacak, Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol. Metab. Clin. North Am. 40(2), 295–311 (2011). https://doi.org/10.1016/j.ecl.2011.02.002
doi: 10.1016/j.ecl.2011.02.002 pubmed: 21565668 pmcid: 3094542
H. Komada, Y. Hirota, A. So, T. Nakamura, Y. Okuno, H. Fukuoka, G. Iguchi, Y. Takahashi, K. Sakaguchi, W. Ogawa, Insulin secretion and insulin sensitivity before and after surgical treatment of pheochromocytoma or paraganglioma. J. Clin. Endocrinol. Metab. 102(9), 3400–3405 (2017). https://doi.org/10.1210/jc.2017-00357
doi: 10.1210/jc.2017-00357 pubmed: 28666346
O. Petrák, D. Haluzíková, P. Kaválková, B. Štrauch, J. Rosa, R. Holaj, A. Brabcová Vránková, D. Michalsky, M. Haluzík, T. Zelinka, J. Widimsky Jr., Changes in energy metabolism in pheochromocytoma. J. Clin. Endocrinol. Metab. 98(4), 1651–1658 (2013). https://doi.org/10.1210/jc.2012-3625
doi: 10.1210/jc.2012-3625 pubmed: 23436923
R.V. Lloyd, R.Y. Osamura, G. Kloppel, J. Rosai, WHO classification of tumours: pathology and genetics of tumours of endocrine organs. 4th ed. (IARC, Lyon), 2017)
A.K. Lam, Update on adrenal tumours in 2017 World Health Organization (WHO) of endocrine tumours. Endocr. Pathol. 28(3), 213–227 (2017). https://doi.org/10.1007/s12022-017-9484-5

Auteurs

Akiyuki Kawashima (A)

Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan.

Masakatsu Sone (M)

Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan. sonemasa@kuhp.kyoto-u.ac.jp.
Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan. sonemasa@kuhp.kyoto-u.ac.jp.
ORCID: 0000-0002-0757-7529

Nobuya Inagaki (N)

Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan.

Kentaro Okamoto (K)

Department of Diabetes, Endocrinology and Nutrition, Kyoto University, Kyoto, Japan.

Mika Tsuiki (M)

Department of Endocrinology and Metabolism, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.

Shoichiro Izawa (S)

Division of Endocrinology and Metabolism, Tottori University Faculty of Medicine, Yonago, Japan.

Michio Otsuki (M)

Department of Metabolic Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.

Shintaro Okamura (S)

Department of Endocrinology, Tenri Hospital, Tenri, Japan.

Takamasa Ichijo (T)

Department of Diabetes and Endocrinology, Saiseikai Yokohamashi Tobu Hospital, Yokohama, Japan.

Takuyuki Katabami (T)

Division of Metabolism and Endocrinology, Department of Internal Medicine, St. Marianna University School of Medicine Yokohama City Seibu Hospital, Yokohama, Japan.

Yoshiyu Takeda (Y)

Department of Internal Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.

Takanobu Yoshimoto (T)

Department of Diabetes and Endocrinology, Tokyo Metropolitan Hiroo Hospital, Tokyo, Japan.
Department of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University, Tokyo, Japan.

Mitsuhide Naruse (M)

Clinical Research Institute of Endocrinology and Metabolism, NHO Kyoto Medical Center and Endocrine Center, Ijinkai Takeda General Hospital, Kyoto, Japan.

Akiyo Tanabe (A)

Division of Endocrinology, National Center for Global Health and Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies endocriniennes › Tumeurs des glandes endocrines › Tumeurs de la surrénale › Pheochromocytoma and paraganglioma with...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Pheochromocytoma and paraganglioma with...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Pheochromocytoma and paraganglioma with...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pheochromocytoma and paraganglioma with...
questionsmedicales.fr › Composés chimiques organiques › Hydrocarbures › Hydrocarbures cycliques › Hydrocarbures aromatiques › Dérivés du benzène › Phénols › Catéchols › Catécholamines › Épinéphrine › Métanéphrine › Pheochromocytoma and paraganglioma with...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Résultats négatifs › Pheochromocytoma and paraganglioma with...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroendocrines › Paragangliome › Pheochromocytoma and paraganglioma with...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs du tissu nerveux › Tumeurs neuroectodermiques › Tumeurs neuroendocrines › Paragangliome › Phéochromocytome › Pheochromocytoma and paraganglioma with...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Pheochromocytoma and paraganglioma with...